Scientists / Our Scientists

Shan Chung

Senior Principal Scientist and Director, Bioanalytical Sciences

Postdoc Mentor

"Curiosity breeds innovation."

Years at Genentech

Publications

Awards & Honors

Shan Chung is currently a Director and Principal Scientist in the Department of BioAnalytical Sciences (BAS), gRED. Shan received his Ph.D. in Molecular Biology from University of Pennsylvania and completed his postdoctoral training in Protein Engineering at Harvard University. Shan has more than 20 years’ experience in research and development of pharmaceutical products, specifically in the areas of preclinical and clinical development of therapeutic antibodies. An expert on Fc effector functions, bioanalytical assays, and immunogenicity of biotherapeutics, Shan serves on the USP Fc Function Expert Panel, and is an active member of the AAPS Working Group on Immunogenicity Risk Assessment and Mitigation. Shan joined Genentech in 2006, and currently leads the Effector Function and Cell Biology group in BAS.

Postdoctoral Mentor

I enjoy the opportunity to work with postdocs on exploratory/research projects which often adds additional excitement and innovation to my work.

Featured Publication

An in vitro FcRn-dependent transcytosis assay as a screening tool for predictive assessment of non-specific clearance of antibody therapeutics in humans.

mAbs 11(5):942-955.

Chung, S., V. Nguyen, L. Lin, et al.

View Abstract on PubMed

A Novel Method for Determining Antibody-Dependent Cellular Phagocytosis.

J. Immunol Methods 468:55-60.

Kamen, L., E. Kho, C. Langsdorf, B. Ordonia, T. Thakurta, and S. Chung.

View Abstract on PubMed

Characterization of in vitro ADCC activity of therapeutic antibodies - impact of effector cells.

J Immunol Methods, 407: 63–75.

Chung, S., Y. L. Lin, C. Reed, C. Ng, Z. J. Cheng, F. Malavasi, J. Yang, V. Quarmby, and A. Song.

View Abstract on PubMed

The responsibilities of my group include biological characterization of clinical candidates, development and validation of bioanalytical assays, and evaluation of immunogenicity potential and pharmacokinetics liability of antibody products.

Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells

mAbs, ISSN: 19420870 19420862

Sivan Cohen; Srividya Myneni; Anna Batt; Joyce Guerrero; Jochen Brumm; Shan Chung

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Shan Chung

Senior Principal Scientist and Director, Bioanalytical Sciences

Featured Publication

An in vitro FcRn-dependent transcytosis assay as a screening tool for predictive assessment of non-specific clearance of antibody therapeutics in humans.

A Novel Method for Determining Antibody-Dependent Cellular Phagocytosis.

Characterization of in vitro ADCC activity of therapeutic antibodies - impact of effector cells.